Opendata, web and dolomites

ADVOS SIGNED

ADVanced Organ Support – Revolution in intensive care for treatment of multiple organ failure

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "ADVOS" data sheet

The following table provides information about the project.

Coordinator
ADVITOS GMBH 

Organization address
address: AGNES POCKELS BOGEN 1
city: MUNICH
postcode: 80992
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 3˙275˙055 €
 EC max contribution 2˙292˙538 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2021-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ADVITOS GMBH DE (MUNICH) coordinator 2˙292˙538.00

Map

 Project objective

60% of intensive care patients die of multiple organ failure (MOF), resulting in a market potential in Western EU of €1.19bn in 13 targeted countries and in the US of €2.05bn. The detoxification organs are nearly always involved in MOF. Therefore, to treat MOF successfully, the vicious cycle of progressing organ failures and increasing toxin accumulation in the body has to be stopped. ADVOS has the potential to revolutionize the therapy of ICU patients worldwide, as it is the first and only ICU device for combined liver, lung, kidney and acid-base support in one device. ADVOS improves survival of patients with MOF from 10 to 50%. No serious side-effects have occurred so far in more than 500 treated patients. Currently, there is no other device in the market that supports all main detoxification organs as the ADVOS system does. As the ADVOS therapy is low-invasive, it can be used by far more intensive care units and can support by far more patients than other devices for e.g. removal of CO2. Although the ADVOS device has the CE mark and is already in the German market (20 first beta user hospitals) the TRL is 6, as we learned in the German market that due to the staff problem and the stressful environment in the ICU the ADVOS usability is by far not good enough to increase revenues more quickly. Therefore, the goal of the SME project ADVOS is faster market entry and penetration through improvement of device usability and ease of use (Integration of accessory components, state of the art turnable touch screen and smart user assistance), integration of IoT for remote access/maintenance in device, and increased marketing and communication measures (Total project cost: 3.3m€ / SME grant amount: 2.3m€).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ADVOS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ADVOS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

HAC (2019)

ADVANCED TREATMENT OF CONTAMINATED SOIL

Read More  

HUD (2018)

COMMERCIALIZING THE FIRST HEAD-UP-DISPLAY FOR OFF-HIGHWAY VEHICLES

Read More